Loading clinical trials...
Loading clinical trials...
A Phase 1 Double-Blinded, Randomized, Placebo-Controlled Study Assessing Safety and Pharmacokinetics of Intramuscular SAB-176 (a Tc Bovine Derived Anti-Influenza Human Immunoglobulin) in Healthy Subjects
Conditions
Interventions
Single Ascending Dose of SAB-176
Single Ascending Dose of Placebo
Locations
1
United States
Naval Medical Research Command (NMRC)
Bethesda, Maryland, United States
Start Date
April 22, 2024
Primary Completion Date
February 1, 2025
Completion Date
February 1, 2025
Last Updated
September 19, 2024
Lead Sponsor
SAb Biotherapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions